Revenue remains negligible at $41,000 for 2026Q1, reflecting a 62.4% year-over-year decline that highlights the company's lack of commercial scale.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Jan'06 |
|---|
| Sales/Revenue | 525K | 593K | 683K | 488K | 386K | 359K | 366K | 244.63K | 378K | 505K | 381K | 313K | 280K | 259.25K | 450K | 257.7K | 265.67K | 650K | 0 |
| Revenue Growth % | -10.71% | -13.18% | 39.96% | 26.42% | 7.52% | -1.91% | 49.61% | -35.28% | -25.15% | 32.55% | 21.73% | 11.79% | 8.01% | -42.39% | 74.62% | -3% | -59.13% | - | - |
| Cost of Goods Sold | 11.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 597K | 1.81M | 1.73M | 629K | 15K | 3.48M | 1.92M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 157.94% | 358.61% | 454.07% | 200.96% | 5.36% | 1342.91% | 426.73% | - | - | - | - |
| Gross Profit | -11.28M | 593K | 683K | 488K | 386K | 359K | 366K | 244.63K | -219K | -1.31M | -1.35M | -316K | 265K | -3.22M | -1.47M | 257.7K | 265.67K | 650K | 0 |
| Gross Margin % | -2147.81% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | -57.94% | -258.61% | -354.07% | -100.96% | 94.64% | -1242.91% | -326.73% | 100% | 100% | 100% | - |
| Gross Profit Growth % | - | -13.18% | 39.96% | 26.42% | 7.52% | -1.91% | 49.61% | 211.7% | 83.23% | 3.19% | -326.9% | -219.25% | 108.22% | -119.15% | -670.56% | -3% | -59.13% | - | - |
| Operating Expenses | 36.15M | 49.55M | 49.33M | 45.9M | 40.29M | 29.21M | 19.45M | 16.92M | 16.17M | 22.11M | 38.01M | 24.96M | 15.21M | 10.95M | 5.3M | 3.23M | 5.64M | 3.05M | 4.41M |
| OpEx % of Revenue | - | 8356.32% | 7223.13% | 9405.74% | 10437.31% | 8137.6% | 5314.75% | 6917.79% | 4277.78% | 4379.21% | 9975.33% | 7973.8% | 5432.14% | 4223.71% | 1177.56% | 1255.16% | 2124.84% | 469.23% | - |
| Selling, General & Admin | 13.02M | 14.22M | 12.48M | 13.04M | 13.18M | 11.84M | 8.22M | 5.76M | 8.01M | 14.23M | 23M | 14.36M | 8.54M | 7M | 3.38M | 2.32M | 1.95M | 2.22M | 2.53M |
| SG&A % of Revenue | - | 2398.65% | 1827.53% | 2672.75% | 3414.77% | 3297.49% | 2245.08% | 2354.92% | 2117.99% | 2818.22% | 6036.48% | 4589.14% | 3051.79% | 2700.99% | 750.95% | 901.77% | 735.48% | 341.54% | - |
| Research & Development | 31.62M | 35.33M | 36.85M | 32.86M | 27.11M | 17.38M | 11.23M | 11.16M | 8.16M | 7.88M | 15.01M | 10.59M | 6.67M | 3.95M | 1.92M | 910.68K | 3.69M | 0 | 1.88M |
| R&D % of Revenue | - | 5957.67% | 5395.61% | 6732.99% | 7022.54% | 4840.11% | 3069.67% | 4562.87% | 2159.79% | 1560.99% | 3938.85% | 3384.66% | 2380.36% | 1522.72% | 426.67% | 353.4% | 1389.35% | - | - |
| Other Operating Expenses | -1.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -170K | -145K | -3K | 0 | 0 | 4K | 0 | 0 | 830K | 0 |
| Operating Income | -47.43M | -48.96M | -48.65M | -45.41M | -39.9M | -28.86M | -19.09M | -16.68M | -17.05M | -25.6M | -40.15M | -25.27M | -14.95M | -10.69M | -4.85M | -2.98M | -5.38M | -2.39M | -8M |
| Operating Margin % | -9033.9% | -8256.32% | -7123.13% | -9305.74% | -10337.31% | -8037.6% | -5214.75% | -6817.79% | -4511.38% | -5068.51% | -10536.75% | -8074.76% | -5337.5% | -4123.71% | -1077.56% | -1155.16% | -2024.84% | -367.69% | - |
| Operating Income Growth % | - | -0.64% | -7.13% | -13.81% | -38.28% | -51.18% | -14.43% | 2.2% | 33.38% | 36.24% | -58.84% | -69.11% | -39.8% | -120.47% | -62.89% | 44.66% | -125.07% | 70.12% | - |
| EBITDA | -46.4M | -48.06M | -48.25M | -45.01M | -39.67M | -28.4M | -18.62M | -16.18M | -16.32M | -24.54M | -39.08M | -24.9M | -14.71M | -10.56M | -4.81M | -2.97M | -5.37M | -2.34M | -8M |
| EBITDA Margin % | -8837.33% | -8103.88% | -7063.98% | -9224.18% | -10276.17% | -7911.98% | -5087.43% | -6615.76% | -4316.64% | -4859.82% | -10256.02% | -7953.77% | -5253.64% | -4073.36% | -1069.15% | -1151.17% | -2021.68% | -360% | - |
| EBITDA Growth % | 10.03% | 0.4% | -7.18% | -13.48% | -39.65% | -52.55% | -15.05% | 0.81% | 33.51% | 37.19% | -56.96% | -69.24% | -39.3% | -119.49% | -62.18% | 44.77% | -129.53% | 70.75% | - |
| D&A (Non-Cash Add-back) | 1.03M | 904K | 404K | 398K | 236K | 451K | 466K | 494.23K | 736.09K | 1.05M | 1.07M | 378.71K | 234.81K | 130.52K | 37.84K | 10.29K | 8.39K | 50K | 0 |
| EBIT | -46.71M | -48.96M | -48.65M | -45.41M | -39.9M | -28.86M | -19.3M | -16.41M | -16.44M | -23.87M | -37.53M | -25.27M | -14.95M | -11.79M | -11.57M | -2.18M | -5.38M | -2.22M | 0 |
| Net Interest Income | 2.67M | 3.1M | 3.26M | 4.07M | 1.58M | 264K | 88K | 234.17K | 194.02K | -886.06K | -1.38M | -1.47M | -831.02K | -13.34K | 0 | -56.47K | -115.4K | 0 | 0 |
| Interest Income | 2.67M | 3.1M | 3.26M | 4.07M | 1.58M | 264K | 90K | 234.17K | 219.43K | 147.88K | 0 | 57.26K | 12K | 3.66K | 0 | 171 | 182 | 0 | 129.16K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 2K | 0 | 25.41K | 1.03M | 1.38M | 1.53M | 843K | 17K | 0 | 56.64K | 115.58K | -90K | 0 |
| Other Income/Expense | 2.67M | 3.11M | 3.22M | 3.97M | 1.2M | 564K | -221K | 264.33K | -72.45K | 689.05K | 941.89K | -2.2M | 619.67K | -1.12M | -6.72M | 699.35K | -69.85K | -90K | 155.63K |
| Pretax Income | -44.77M | -45.85M | -45.43M | -41.44M | -38.7M | -28.29M | -19.31M | -16.41M | -16.46M | -24.91M | -39.2M | -27.47M | -14.32M | -11.81M | -11.57M | -2.28M | -5.33M | -2.48M | -7.84M |
| Pretax Margin % | -8527.24% | -7732.04% | -6651.68% | -8492.01% | -10026.94% | -7880.5% | -5275.14% | -6709.74% | -4354.76% | -4932.08% | -10289.76% | -8776.68% | -5116.07% | -4555.88% | -2570.22% | -883.77% | -2007.69% | -381.54% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 617.64K | 716K | -296K | 1.82M | 608.19K | 17K | 6.68M | -737.59K | 69.85K | -180K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -3.75% | -2.87% | 0.76% | -6.61% | -4.25% | -0.14% | -57.78% | 32.39% | -1.31% | 7.26% | 0% |
| Net Income | -44.77M | -45.85M | -45.43M | -41.44M | -38.7M | -28.29M | -19.31M | -16.41M | -16.46M | -24.91M | -39.2M | -27.47M | -14.32M | -11.81M | -11.57M | -2.24M | -5.45M | -2.48M | -7.84M |
| Net Margin % | -8527.24% | -7732.04% | -6651.68% | -8492.01% | -10026.94% | -7880.5% | -5275.14% | -6709.74% | -4354.76% | -4932.08% | -10289.76% | -8776.68% | -5116.07% | -4555.88% | -2570.22% | -868.94% | -2051.13% | -381.54% | - |
| Net Income Growth % | 8.36% | -0.92% | -9.63% | -7.07% | -36.81% | -46.53% | -17.62% | 0.28% | 33.91% | 36.47% | -42.71% | -91.77% | -21.29% | -2.12% | -416.52% | 58.91% | -119.72% | 68.38% | - |
| Net Income (Continuing) | -44.77M | -45.85M | -45.43M | -41.44M | -38.7M | -28.29M | -19.31M | -16.41M | -16.46M | -24.91M | -39.2M | -27.47M | -14.33M | -11.81M | -11.57M | -2.24M | -5.45M | -2.48M | -7.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.66 | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | -2.70 | -7.06 | -51.71 | -93.22 | -74.77 | -54.08 | -50.09 | -63.73 | -16.60 | -54.81 | -35.43 | -7.55 |
| EPS Growth % | 35.58% | 27.37% | -2.15% | -4.49% | -21.92% | 32.41% | 60% | 61.76% | 86.35% | 44.53% | -24.68% | -38.26% | -7.97% | 21.4% | -283.92% | 69.71% | -54.7% | -369.27% | - |
| EPS (Basic) | - | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | -2.70 | -7.06 | -51.71 | -93.54 | -75.49 | -54.56 | -50.27 | -63.87 | -16.60 | -54.81 | -35.43 | -7.55 |
| Diluted Shares Outstanding | 68.35M | 66.84M | 47.65M | 44.68M | 43.6M | 39.03M | 20.88M | 5.97M | 2.33M | 481.67K | 420.57K | 367.39K | 264.87K | 235.81K | 181.49K | 134.88K | 99.43K | 70K | 1.04M |
| Basic Shares Outstanding | 68.35M | 66.84M | 47.65M | 44.68M | 43.6M | 39.03M | 20.88M | 5.97M | 2.33M | 481.67K | 419.1K | 363.92K | 262.56K | 234.94K | 181.09K | 134.88K | 99.43K | 70K | 1.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Clinical trial funding insolvency
As indicated by the most recent quarterly filings, CRDF reported revenue of only $41,000, representing a significant 62.4% year-over-year decline that underscores the company's current status as a pre-commercial entity reliant on non-recurring, transactional milestones rather than a sustainable or predictable product-driven growth engine.
The revenue volatility observed over the last ten quarters confirms that the company lacks a recurring commercial base. Investors should interpret these figures as incidental accounting entries rather than indicators of market adoption or competitive success.
Based on the provided financial statements, the company's cost structure is almost entirely comprised of research and development expenditures, which reached $6.8 million in 2026Q1, consistently dwarfing the minimal revenue and forcing the firm into a persistent state of deep operating losses.
The high concentration of spending on clinical trial execution suggests that management is prioritizing pipeline advancement over operational efficiency. This expense profile is typical for the sector but highlights the extreme sensitivity of the firm's survival to the successful completion of clinical milestones.
According to the income statement data, CRDF consistently issues stock-based compensation, with $1.7 million recorded in 2026Q1, which effectively serves to dilute existing shareholders while masking the true cash-based operating expenses required to sustain the company's ongoing clinical development programs.
The reliance on equity-based incentives appears to be a mechanism for preserving cash, yet it complicates the assessment of the company's true burn rate. Analysts should monitor the relationship between SBC and the total operating loss to gauge the real economic cost of talent retention.
As reported in recent financial disclosures, the company's operating loss of $12.8 million in 2026Q1 against a limited cash position suggests that the firm may face significant liquidity constraints, potentially necessitating further dilutive financing to maintain its current clinical trial trajectory in the near term.
The disparity between the current cash position and the quarterly burn rate warrants extreme caution regarding the company's ability to fund operations without external capital. Investors should consider the high probability of future equity raises as a primary risk to the current valuation.
Quick answers to the most common questions about buying CRDF stock.
For fiscal year 2025, Cardiff Oncology, Inc. (CRDF) reported total revenue of $0.6M.
Cardiff Oncology, Inc. (CRDF) reported a net loss of $45.9M for the fiscal year ending 2025.
Cardiff Oncology, Inc. (CRDF) reported an operating income of $-49.0M, resulting in an operating profit margin of -8256.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Cardiff Oncology, Inc. (CRDF) generated $0.6M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.